Eli Lilly announced it will acquire three vaccine developers—Curevo, LimmaTech Biologics AG, and Vaccine Company—in deals totaling up to $3.83 billion. This strategic move expands Lilly's focus into infectious disease prevention, complementing its existing portfolio in diabetes and obesity. The acquisitions bring promising vaccine candidates targeting shingles, bacterial infections, and Epstein-Barr Virus, with several programs in clinical trials. This push into vaccines aims to address global health challenges by emphasizing prevention over treatment.
Lilly has agreed to acquire Curevo Vaccine, a biotech firm developing a next-generation shingles vaccine called amezosvatein, designed to improve tolerability and increase vaccination rates. The deal could pay Curevo shareholders up to $1.5 billion, ...
Eli Lilly announced plans to acquire Curevo, LimmaTech Biologics, and Vaccine Company for a total of nearly $4 billion in cash. This move aims to expand Eli Lilly's research and development efforts into infectious diseases, focusing on preventing dis...
Eli Lilly announced agreements to acquire Curevo, LimmaTech Biologics, and Vaccine Company to expand its infectious disease research. These acquisitions focus on developing vaccines targeting viral and bacterial pathogens linked to long-term health r...
Eli Lilly reported positive Phase 1b results for VERVE-102, a gene therapy that permanently silences the PCSK9 gene to reduce LDL cholesterol by up to 62%. The therapy showed sustained effects for up to 18 months and was well-tolerated with no seriou...
Eli Lilly reported Phase III data for its weight loss drug retatrutide showing strong dose-dependent efficacy, with up to 30% weight loss at 104 weeks in patients with BMI over 35. UBS analysts highlight the drug's potential to differentiate itself i...
